Pirtobrutinib
Pirtobrutinib (LOXO-305) is a highly selective, non-covalent next-generation BTK inhibitor effective against wild-type and C481-mutant BTK (IC50s = 10-100 nM and <10 nM, respectively). It is over 300-fold selective for BTK versus 370 other kinases and does not significantly inhibit non-kinase off-targets at 1 μM. Pirtobrutinib induces regression of BTK-dependent lymphoma tumors in mouse xenograft models and reduces Ki67-positive proliferating cells in MEC-1 chronic lymphocytic leukemia (CLL) models. Reagent grade, for research use only.

-
Catalog:
BP-43653
-
Name:
Pirtobrutinib
-
Formula:
C22H21F4N5O3
-
MW:
479.4
-
CAS:
2101700-15-4
-
Purity:
-
Ships Within:
24 Hours
-
Storage Condition:
-20°C
-
Shipping:
Ambient Temperature
-
NMR:
View
-
SDS:
Inquire about MSDS